Abstract:Summary Background Disparate and rapidly changing practice recommendations from major professional infectious diseases societies for managing non-severe infections caused by extended-spectrum β-lactamase-producing Enterobacterales might hamper carbapenem stewardship. We aimed to understand the real-world management of extended-spectrum cephalosporin-resistant (ECR) Enterobacterales infections in US hospitals and factors influencing preference for carbapenems over alternative treatments. Methods This retrospective cohort study included adults (aged ≥18 years) admitted to hospital with ECR Enterobacterales infections in the PINC AI database. Antibiotic regimens were assessed during empirical and targeted treatment periods and by infection severity and site. Likelihood of receiving targeted carbapenems over time and before or after initial release of the Infectious Diseases Society of America (IDSA) guidance on Sept 8, 2020, was established with generalised estimating equations controlling for patient, hospital, and temporal confounders. Findings Between Jan 1, 2018, and Dec 31, 2021, 30 041 inpatient encounters with ECR Enterobacterales infections were identified at 168 US hospitals, of which 16 006 (53·3%) encounters were in women and 14 035 (46·7%) were in men, with a mean age of 67·3 years (SD 15·1). Although few patients received carbapenems empirically (5324 [17·7%] of 30 041), many did so as targeted treatment (17 518 [58·3%] of 30 041), including subgroups of patients without septic shock (3031 [45·6%] of 6651) and patients with urinary tract infections without septic shock (1845 [46·8%] of 3943) in whom specific narrower-spectrum alternatives were active. Transitions from non-carbapenem to carbapenem antibiotics occurred most often on the day that the ECR phenotype was reported, regardless of illness severity. Carbapenems were the predominant choice to treat ECR Enterobacterales infections over time (adjusted odds ratio 1·00 [95% CI 1·00–1·00]), with no additional immediate change (1·07 [0·95–1·20]) or sustained change (0·99 [0·98–1·00]) after IDSA guidance release. Interpretation High carbapenem use in targeting non-severe ECR Enterobacterales infections in US hospitals predates 2020 IDSA guidance and has persisted thereafter. Efforts to increase awareness and implementation of recommendations among clinicians to use carbapenem-sparing alternatives in ECR Enterobacterales infections might decrease global carbapenem selective pressure. Funding US National Institutes of Health Intramural Research Program, National Institute of Allergy and Infectious Diseases, and US Food and Drug Administration.

Evaluation of Carbapenem Use in a Tertiary Hospital: Antimicrobial Stewardship Urgently Needed

Effectiveness of Continuous Improvement by a Clinical Pharmacist-Led Guidance Team on the Prophylactic Antibiotics Usage Rationality in Intervention Procedure at a Chinese Tertiary Teaching Hospital

Antibiotic Consumption Versus the Prevalence of Carbapenem-Resistant Gram-negative Bacteria at a Tertiary Hospital in China from 2011 to 2017.

Active Surveillance of Carbapenem-Resistant Gram-Negative Bacteria to Guide Antibiotic Therapy: a Single-Center Prospective Observational Study

Prevalence and Mechanisms of Carbapenem Resistance among Klebsiella Aerogenes in a Tertiary Hospital in China

Pharmacist-led Quality Control Circle in Sustained Reduction of Carbapenem-Resistance at a Chinese Tertiary Teaching Hospital.

Impact of a national antibiotic stewardship intervention in China targeting carbapenem overuse: an interrupted time-series analysis

Effect of a National Antibiotic Stewardship Intervention in China Targeting Carbapenem Overuse: an Interrupted Time-Series Analysis.

PMU28 CLINICAL AND ECONOMIC OUTCOMES OF CARBAPENEM-RESISTANT GRAM-NEGATIVE ORGANISMS: A MULTICENTER STUDY IN CHINA

PMU82 EFFECT OF CARBAPENEM RESISTANCE ON TOTAL HOSPITALIZATION COSTS AMONG INPATIENTS WITH PSEUDOMONAS AERUGINOSA: A MULTICENTER STUDY IN CHINA

Retrospective Survey of the Efficacy of Mandatory Implementation of the Essential Medicine Policy in the Primary Healthcare Setting in China: Failure to Promote the Rational Use of Antibiotics in Clinics.

Association between antibiotic consumption and the rate of carbapenem-resistant Gram-negative bacteria from China based on 153 tertiary hospitals data in 2014

Temporal Association Between Carbapenems Usage and Antimicrobial Resistance in Gram-Negative Bacteria at a Tertiary Hospital in Nanjing, China

Change in Antibiotic Use in Secondary and Tertiary Hospitals Nationwide after a National Antimicrobial Stewardship Campaign Was Launched in China, 2011-2016: an Observational Study.

Impact of a Special National Antimicrobial-Stewardship Campaign in China: Irrational Antibiotics Use Was Greatly Decreased but Formidable Problems Remain to Be Overcome

Carbapenem use in extended-spectrum cephalosporin-resistant Enterobacterales infections in US hospitals and influence of IDSA guidance: a retrospective cohort study

Investigation and analysis of carbapenem-resistant gram-negative bacterial infection rates across hospitals in Shandong Province in China

Impact of a program combining pre-authorization requirement and post-prescription review of carbapenems: an interrupted time-series analysis

Risk factors correlated with antibiotic-induced carbapenem resistant in Gram-negative bacilli in China: a retrospective cohort study

Different Effects of Antibiotics on Klebsiella pneumoniae and Escherichia coli Resistance Induced by Antibiotics: A Retrospective Study from China

Analysis of Risk Factors and Clinical Outcome for Carbapenems-resistant Pseudomonas aeruginosa Infection in Our Hospital from 2013 to 2016